Genomic test to predict prostate cancer progression, 5/16

May 2016—GenomeDx Biosciences launched Decipher Biopsy, a genomic test that evaluates RNA expression-based biomarkers to predict the risk of high-grade disease, metastasis, and cancer-specific death at the time of biopsy in men with prostate cancer. The launch brings the Decipher Prostate Cancer Classifier to newly diagnosed patients at initial biopsy. The company says Decipher Biopsy is the only genomic test available to assess tumor aggressiveness across very low-, low-, intermediate-, and high-risk patients, enabling physicians to accurately determine if the patient may safely consider delaying initial local treatment or if he may benefit from earlier intensification of treatment with one or more therapies.

GenomeDx Biosciences, 888-975-4540